Prognostic biomarkers in patients with localized natural killer/T‐cell lymphoma treated with concurrent chemoradiotherapy

Cancer Science

Motoko Yamaguchi⁶  Katsuyoshi Takata⁹  Tadashi Yoshino⁹  Naoki Ishizuka¹⁰  Masahiko Oguchi¹⁴  Yukio Kobayashi¹⁵  Yasushi Isobe⁷  Kenichi Ishizawa¹  Nobuko Kubota⁴  Kuniaki Itoh¹³  Noriko Usui^6,11  Kana Miyazaki⁶  Izumi Wasada^2,6  Shigeo Nakamura^3,6  Yoshihiro Matsuno^6,8  Kazuo Oshimi^6,12  Tomohiro Kinoshita^5,6  Kunihiro Tsukasaki¹³ 

[1] Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan;Department of Hematology, Tokai University, Isehara, Japan;Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan;Department of Hematology, Saitama Cancer Center, Ina, Japan;Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan;Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan;Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan;Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;Clinical Trial Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;Division of Hematology and Oncology, Jikei University School of Medicine, Tokyo, Japan;Department of Internal Medicine, Kushiro Chuo Hospital, Kushiro, Japan;Division of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan;Department of Radiation Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

关键词: Clinical trial;    Epstein–Barr virus;    extranodal NK/T‐cell lymphoma;    latent membrane protein 1;    radiotherapy;   

DOI  :  10.1111/cas.12526

来源: Wiley

【 摘 要 】

Abstract

Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61–94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057–1.013; 80% CI, 0.093–0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy.

【 授权许可】

CC BY-NC-ND   
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.